COVID-19 pandemic may be accelerating antimicrobial resistance: new US study published

COVID-19 pandemic may be accelerating antimicrobial resistance: new US study published

  • 02/05/2022

A new study by BD (Becton Dickinson) and MSD (Merck & Co.) found higher rates of antibiotic-resistant infections in both COVID-19-infected and non-infected patients admitted during the pandemic compared to the pre-pandemic data, after analyzing antimicrobial resistance cases in a total of 271 US hospitals.

The findings were presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal (23-26 April).

The study, by Dr Karri Bauer of the pharmaceutical company MSD, a trade name of Merck & Co., Inc, Kenilworth, NJ, USA and Dr Vikas Gupta, of the medical technology company Becton Dickinson (BD) and colleagues, also found that drug resistant infections were significantly higher in hospital-onset cases during the pandemic.

Read more: https://www.escmid.org/fileadmin/src/media/PDFs/2News_Discussions/Press_activities/2022/2022-04-25-US_study_suggests.pdf